Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers.

Lal R, Sukbuntherng J, Ho J, Cundy KC.

Int J Clin Pharmacol Ther. 2011 Feb;49(2):109-15.

PMID:
21255527
2.

Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome.

Merlino G, Serafini A, Young JJ, Robiony F, Gigli GL, Valente M.

Curr Opin Investig Drugs. 2009 Jan;10(1):91-102.

PMID:
19127491
3.

Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.

Lal R, Sukbuntherng J, Luo W, Chen D, Vu A, Tovera J, Cundy KC.

Clin Ther. 2009 Aug;31(8):1776-86. doi: 10.1016/j.clinthera.2009.07.026.

PMID:
19808136
4.

Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.

Lal R, Sukbuntherng J, Luo W, Tovera J, Lassauzet ML, Cundy KC.

J Clin Pharmacol. 2013 Jan;53(1):29-40. doi: 10.1177/0091270012439209. Epub 2013 Jan 24.

PMID:
23400741
5.

A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome.

Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, Tovera J, Hurt J, Bonzo D, Lassauzet ML, Vu A, Cundy KC.

Clin Neuropharmacol. 2012 Jul-Aug;35(4):165-73. doi: 10.1097/WNF.0b013e318259eac8.

PMID:
22664749
6.

Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.

Chen D, Lal R, Zomorodi K, Atluri H, Ho J, Luo W, Tovera J, Bonzo D, Cundy K.

Clin Ther. 2012 Feb;34(2):351-362.e3. doi: 10.1016/j.clinthera.2012.01.002.

PMID:
22325733
7.

Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine.

Lal R, Sukbuntherng J, Luo W, Vicente V, Blumenthal R, Ho J, Cundy KC.

Br J Clin Pharmacol. 2010 May;69(5):498-507. doi: 10.1111/j.1365-2125.2010.03616.x.

8.

Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.

Lal R, Sukbuntherng J, Luo W, Chen D, Blumenthal R, Ho J, Cundy KC.

Clin Ther. 2012 Jan;34(1):201-13. doi: 10.1016/j.clinthera.2011.12.004. Epub 2011 Dec 28.

PMID:
22206794
9.

Gabapentin enacarbil for treatment of restless legs syndrome in adults.

Hayes WJ, Lemon MD, Farver DK.

Ann Pharmacother. 2012 Feb;46(2):229-39. doi: 10.1345/aph.1Q578. Epub 2012 Jan 31. Review.

PMID:
22298601
10.

Gabapentin enacarbil for the treatment of restless legs syndrome (RLS).

Burke RA, Faulkner MA.

Expert Opin Pharmacother. 2011 Dec;12(18):2905-14. doi: 10.1517/14656566.2011.635645. Epub 2011 Nov 14. Review.

PMID:
22077768
11.

The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil.

Lal R, Sukbuntherng J, Luo W, Huff FJ, Zou J, Cundy KC.

Int J Clin Pharmacol Ther. 2010 Feb;48(2):120-8.

PMID:
20137764
12.

A 52-week study of gabapentin enacarbil in restless legs syndrome.

Ellenbogen AL, Thein SG, Winslow DH, Becker PM, Tolson JM, Lassauzet ML, Chen D.

Clin Neuropharmacol. 2011 Jan-Feb;34(1):8-16. doi: 10.1097/WNF.0b013e3182087d48.

PMID:
21242741
13.

Gabapentin enacarbil in restless legs syndrome.

Merlino G, Serafini A, Lorenzut S, Sommaro M, Gigli GL, Valente M.

Drugs Today (Barc). 2010 Jan;46(1):3-11. doi: 10.1358/dot.2010.46.1.1424766. Review.

PMID:
20200691
14.

Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial.

Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP045 Study Group.

Clin Neuropharmacol. 2009 Nov-Dec;32(6):311-20. doi: 10.1097/WNF.0b013e3181b3ab16.

PMID:
19667976
15.

Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome.

Imamura S, Kushida C.

Expert Opin Pharmacother. 2010 Aug;11(11):1925-32. doi: 10.1517/14656566.2010.494598. Review.

PMID:
20629607
16.

Gabapentin enacarbil: in patients with restless legs syndrome.

Scott LJ.

CNS Drugs. 2012 Dec;26(12):1073-83. doi: 10.1007/s40263-012-0020-3. Review. Erratum in: CNS Drugs. 2013 Feb;27(2):163-4. CNS Drugs. 2013 Jan;27(1):81.

PMID:
23179641
17.

[Pharmacological and clinical profile of gabapentin enacarbil: a novel drug for the treatment of restless legs syndrome].

Kakimoto S, Ozawa T, Igarashi K, Tokuno T, Kaku S, Seki N.

Nihon Yakurigaku Zasshi. 2012 Aug;140(2):85-92. Review. Japanese. No abstract available.

PMID:
22878573
18.

Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome.

Winkelman JW, Bogan RK, Schmidt MH, Hudson JD, DeRossett SE, Hill-Zabala CE.

Mov Disord. 2011 Sep;26(11):2065-72. doi: 10.1002/mds.23771. Epub 2011 May 24.

PMID:
21611981
19.

Gabapentin encarbil (Horizant) for restless leg syndrome.

[No authors listed]

Med Lett Drugs Ther. 2011 Sep 5;53(1372):70-1.

PMID:
21897349
20.

Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.

Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM.

J Clin Pharmacol. 2008 Dec;48(12):1378-88. doi: 10.1177/0091270008322909. Epub 2008 Sep 30.

PMID:
18827074

Supplemental Content

Support Center